Be in the know. 20 key reads for Wednesday…

  1. Higher Bond Yields Likely to Extend Fed Rate Pause. Officials are signaling that a run-up in long-term interest rates might substitute for a further central bank rate hike (wsj)
  2. General Motors reaches deal with Canadian autoworkers hours after union initiates strikes (cnbc)
  3. Why the Weight-Loss Drug Hype Looks Overdone (barrons)
  4. GLP-1 drugs are still in demand. Insurers are cutting back coverage in response, Found study shows (fiercehealthcare)
  5. Ozempic Won’t Kill Americans’ Taste for Sugary Snacks (barrons)
  6. Janet Yellen Suggests Much Lower For Much Longer (zerohedge)
  7. Wholesale inflation accelerates more than expected in September (foxbusiness)
  8. Emerging-market stocks are looking cheap, especially relative to the U.S. Does that mean it is time to buy? (marketwatch)
  9. Dividend stocks are dirt cheap. It may be time to back up the truck. (marketwatch)
  10. Samsung Reports 78% Drop in Profit. Why It Could Be Good News for Micron and Intel. (barrons)
  11. Age-old excellence NYC’s best new restaurant is a 186-year-old steakhouse (com)
  12. 104-year-old woman dies after breaking world record for oldest skydiver (nypost)
  13. The Fed tool that is having a powerful impact (ft)
  14. Ozempic Shows Promise Treating Kidney Failure in Blow to Dialysis Firms (bloomberg)
  15. What You Need to Know About Drugs Like Wegovy Being Used for Weight Loss (bloomberg)
  16. Ten-year Treasury yield hits two-week low ahead of Fed minutes (marketwatch)
  17. Boeing’s deliveries and production of the company’s bestselling jet slowed in September amid snafus at one of its key suppliers (wsj)
  18. Lotus Inks Deal With Santander to Finance Sports Car Loans in US (bloomberg)
  19. CHART OF THE DAY: A bullish formula for the stock market is brewing as the Nasdaq follows 1999 playbook (businessinsider)
  20. Dialysis-company stocks slide after Ozempic trial’s success in treating kidney disease (marketwatch)